MBRX: Moleculin Biotech Inc. Stocks News on April 4, 2025

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

MBRX

TipRanks

2 days ago

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

Moleculin Biotech begins dosing subjects in combination therapy trial for AML

MBRX

Clinical Trials Arena

2 days ago

Moleculin Biotech begins dosing subjects in combination therapy trial for AML

MBRX

Zacks

3 days ago

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

MBRX

GlobeNewswire

3 days ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

MBRX

Zacks

9 days ago

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy

MBRX

GuruFocus.com

10 days ago

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...

MBRX

Thomson Reuters StreetEvents

10 days ago

Q4 2024 Moleculin Biotech Inc Earnings Call

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

MBRX

GlobeNewswire

11 days ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

MBRX

GlobeNewswire

16 days ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

MBRX

PR Newswire

24 days ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

MBRX

PR Newswire

25 days ago

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

MBRX

PR Newswire

a month ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

MBRX

PR Newswire

a month ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

MBRX

MT Newswires

a month ago

Moleculin Biotech Prices $3.5 Million Direct Offering; Shares Rise

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

MBRX

PR Newswire

a month ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

MBRX

MT Newswires

2 months ago

Moleculin Biotech Expects to Raise $5.8 Million From Exercise of Warrants

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

MBRX

Benzinga

2 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

MBRX

PR Newswire

2 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

MBRX

PR Newswire

2 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine

MBRX

Clinical Trials Arena

2 months ago

Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine

MBRX

MT Newswires

2 months ago

Moleculin Biotech Receives Approval in Ukraine to Start Recruiting for Acute Myeloid Leukemia Phase 3 Trial

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

MBRX

PR Newswire

2 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Participates in Virtual Investor "What This Means" Segment

MBRX

PR Newswire

2 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

MBRX

PR Newswire

3 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

MBRX

MT Newswires

4 months ago

Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

MBRX

PR Newswire

4 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

MBRX

PR Newswire

5 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

MBRX

PR Newswire

5 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Biotech Reports Financial Highlights and Future Plans

MBRX

TipRanks

5 months ago

Moleculin Biotech Reports Financial Highlights and Future Plans

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

MBRX

PR Newswire

5 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

MBRX

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Moleculin Biotech Inc Earnings Call

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

MBRX

PR Newswire

5 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

MBRX

PR Newswire

5 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

MBRX

PR Newswire

5 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Moleculin Biotech Highlights Annamycin’s AML Treatment Potential

MBRX

TipRanks

6 months ago

Moleculin Biotech Highlights Annamycin’s AML Treatment Potential

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

MBRX

PR Newswire

6 months ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

MBRX

GuruFocus.com

6 months ago

Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

MBRX

PR Newswire

6 months ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Moleculin to Present at Two Upcoming Investor Conferences

MBRX

PR Newswire

6 months ago

Moleculin to Present at Two Upcoming Investor Conferences

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

MBRX

PR Newswire

6 months ago

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

MBRX

PR Newswire

7 months ago

Moleculin Participates in Virtual Investor "What this Means" Segment

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

MBRX

PR Newswire

7 months ago

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MBRX

PR Newswire

7 months ago

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

MBRX

PR Newswire

7 months ago

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Moleculin Announces Closing of up to $16.5 Million Public Offering

MBRX

PR Newswire

8 months ago

Moleculin Announces Closing of up to $16.5 Million Public Offering

MBRX

MT Newswires

8 months ago

Moleculin Biotech Prices Up to $16.5 Million Public Offering

Moleculin Announces Pricing of up to $16.5 Million Public Offering

MBRX

PR Newswire

8 months ago

Moleculin Announces Pricing of up to $16.5 Million Public Offering

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

MBRX

PR Newswire

8 months ago

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

MBRX

PR Newswire

8 months ago

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

MBRX

PR Newswire

9 months ago

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

MBRX

PR Newswire

10 months ago

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

Moleculin to Present at the Virtual Investor Pitch Conference

MBRX

PR Newswire

10 months ago

Moleculin to Present at the Virtual Investor Pitch Conference

Moleculin to Participate in the Virtual Investor Lunch Break Series

MBRX

PR Newswire

10 months ago

Moleculin to Participate in the Virtual Investor Lunch Break Series

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

MBRX

PR Newswire

a year ago

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

Moleculin begins NIH-funded Phase II glioblastoma treatment trial

MBRX

Clinical Trials Arena

a year ago

Moleculin begins NIH-funded Phase II glioblastoma treatment trial

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

MBRX

PR Newswire

a year ago

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

MBRX

GuruFocus.com

a year ago

Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

MBRX

PR Newswire

a year ago

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

MBRX

PR Newswire

a year ago

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

MBRX

PR Newswire

a year ago

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

MBRX

PR Newswire

a year ago

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

MBRX

PR Newswire

a year ago

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

MBRX

PR Newswire

a year ago

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

MBRX

ACCESSWIRE

a year ago

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

MBRX

PR Newswire

a year ago

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

MBRX

PR Newswire

a year ago

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

MBRX

PR Newswire

a year ago

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

MBRX

PR Newswire

a year ago

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

MBRX

PR Newswire

a year ago

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

MBRX

Insider Monkey

a year ago

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

MBRX

PR Newswire

a year ago

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results

MBRX

GuruFocus.com

a year ago

Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results

Moleculin Reports Full Year 2023 Financial Results

MBRX

PR Newswire

a year ago

Moleculin Reports Full Year 2023 Financial Results

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

MBRX

PR Newswire

a year ago

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

MBRX

PR Newswire

a year ago

Moleculin Announces Reverse Stock Split

Moleculin to Present at the 36th Annual ROTH Conference

MBRX

PR Newswire

a year ago

Moleculin to Present at the 36th Annual ROTH Conference

An Intrinsic Calculation For Information Services Corporation (TSE:ISV) Suggests It's 45% Undervalued

MBRX

Simply Wall St.

a year ago

An Intrinsic Calculation For Information Services Corporation (TSE:ISV) Suggests It's 45% Undervalued

Palatin Announces $10 Million Registered Direct Offering

MBRX

PR Newswire

a year ago

Palatin Announces $10 Million Registered Direct Offering

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

MBRX

GlobeNewswire

a year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

MBRX

Associated Press Finance

a year ago

FS Bancorp: Q4 Earnings Snapshot

FS Bancorp, Inc. Reports $36.1 Million of Net Income or $4.56 Per Diluted Share for 2023 and a 4% Increase in its Quarterly Dividend to $0.26 Per Share

MBRX

GlobeNewswire

a year ago

FS Bancorp, Inc. Reports $36.1 Million of Net Income or $4.56 Per Diluted Share for 2023 and a 4% Increase in its Quarterly Dividend to $0.26 Per Share

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

MBRX

PR Newswire

a year ago

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

MBRX

GlobeNewswire

a year ago

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

Talkspace and the American Federation of Teachers Join Forces to Enhance Mental Health Support for Educators, Healthcare and Public Workers

MBRX

Business Wire

a year ago

Talkspace and the American Federation of Teachers Join Forces to Enhance Mental Health Support for Educators, Healthcare and Public Workers

INNO Holdings and ASP Isotopes Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

MBRX

ACCESSWIRE

a year ago

INNO Holdings and ASP Isotopes Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

MBRX

GlobeNewswire

a year ago

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

MBRX

PR Newswire

a year ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

MBRX

PR Newswire

a year ago

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

Sunrise New Energy Files for China Patent Award, the Highest Honor in Intellectual Property Rights

MBRX

GlobeNewswire

a year ago

Sunrise New Energy Files for China Patent Award, the Highest Honor in Intellectual Property Rights

Talkspace to Present at the 26th Annual Needham Growth Conference

MBRX

GlobeNewswire

a year ago

Talkspace to Present at the 26th Annual Needham Growth Conference

3 Natural Food Stocks in Focus on Impressive Industry Trends

MBRX

Zacks

a year ago

3 Natural Food Stocks in Focus on Impressive Industry Trends

MBRX

Newsfile

a year ago

PetVivo Holdings, Inc. Invites You to Join Us at The Microcap Conference

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

MBRX

Zacks

a year ago

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

Colony Bank Donates $400,000 to 10 Rural Hospitals Across Georgia

MBRX

Business Wire

a year ago

Colony Bank Donates $400,000 to 10 Rural Hospitals Across Georgia

$SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients$

MBRX

GlobeNewswire

a year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

PETVIVO HOLDINGS, INC. TO EXHIBIT AT VETERINARY MEETING AND EXPO CONFERENCE IN ORLANDO, FLORIDA

MBRX

GlobeNewswire

a year ago

PETVIVO HOLDINGS, INC. TO EXHIBIT AT VETERINARY MEETING AND EXPO CONFERENCE IN ORLANDO, FLORIDA

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

MBRX

GlobeNewswire

a year ago

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

MBRX

GlobeNewswire

a year ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Is Now The Time To Look At Buying Tuniu Corporation (NASDAQ:TOUR)?

MBRX

Simply Wall St.

a year ago

Is Now The Time To Look At Buying Tuniu Corporation (NASDAQ:TOUR)?

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

MBRX

GlobeNewswire

a year ago

Latest Moleculin Biotech Inc. (MBRX) News on April 4, 2025

Share on Social Networks: